Metsera
Biopharma Deal Activity Shows Uptick in Q3 2025: Signs of Recovery and Emerging Trends
biopharma; Q3 2025; deal activity; M&A; licensing; therapeutic diversification; early-stage assets; China; US; Europe; Metsera; Verona Pharma; Merus; high-value deals
Metsera’s New Obesity Data Raises Efficacy Profile, Key Side Effect Questions for Pfizer After Acquisition
Metsera; Pfizer; obesity drug; MET-097i; GLP-1; side effects; efficacy; Phase 2 trial; weight loss; Pfizer acquisition
Pfizer’s $4.9B Metsera Deal Signals More Pharma M&A in Booming Obesity Drug Market
Pfizer; Metsera; obesity drugs; weight loss; pharma M&A; GLP-1; biotech acquisition; pharmaceutical market; late-stage clinical development
Pfizer Acquires Metsera to Compete with Zepbound in Obesity Market
Pfizer; Metsera; obesity treatment; Zepbound; GLP-1 therapies; MET-233i; monthly dosing; amylin mimetic; MET-097i; acquisition; clinical trials
Metsera Reports Once-Monthly Amylin Analogue Matches GLP-1 Efficacy in Early Phase 1 Results
Metsera; MET-233i; amylin; obesity; weight-loss; GLP-1; once-monthly; clinical trial; phase 1
Metsera and Maze Therapeutics Raise $415 Million in Successful Biotech IPOs
Biotech IPOs, Metsera, Maze Therapeutics, obesity treatment, kidney disease, NASDAQ listings, pharmaceutical funding
Biotech IPO Momentum: Maze and Metsera’s Dual Debut Signals Renewed Market Optimism
Biotech IPOs, Maze Therapeutics, Metsera, obesity treatment, precision medicine, market optimism, 2025 IPO trends
Metsera Raises $275M in IPO to Advance GLP-1 Weight Loss Drug to Phase 3
Metsera, IPO, GLP-1 receptor agonist, MET-097i, obesity treatment, weight loss drug, clinical trials, biotech funding
Metsera Advances with Positive Phase IIa Results for Monthly GLP-1RA Dosing
Metsera, GLP-1RA, MET-097i, obesity treatment, monthly dosing, weight loss, clinical trials
Metsera Secures $215M to Accelerate Obesity Drug Development
Metsera, Obesity Drug, Funding, Biotech, GLP-1, Metabolic Disease